Age-related muscle decline affects virtually every adult over 50, yet no approved medications exist to combat this inevitable deterioration. The paradox has been finding interventions that strengthen aging muscle without disrupting metabolic balance or triggering unwanted side effects.
Investigators discovered that eliminating or blocking ghrelin receptors—proteins typically associated with hunger and growth hormone release—dramatically improved muscle endurance and strength in aging male mice. Animals lacking these receptors maintained superior fatigue resistance and force generation at 24 and 28 months compared to normal counterparts, despite no changes in overall muscle mass. When researchers administered PF-5190457, a compound that blocks ghrelin receptor activity, similar improvements emerged in muscle performance metrics.
The mechanism centers on mitochondrial enhancement within muscle fibers. Ghrelin receptor suppression elevated PGC-1α, a master regulator of mitochondrial production, while optimizing cellular cleanup processes that remove damaged mitochondria through specialized pathways involving PINK1, LC3II, and Bnip3 proteins. Proteomics analysis confirmed mitochondrial components as central drivers of muscle preservation during aging.
This finding challenges conventional thinking about ghrelin's role in muscle health. While ghrelin typically promotes appetite and has short-term muscle-building effects, chronic receptor activation may actually impair long-term muscle quality. The research suggests pharmacological ghrelin receptor antagonism could represent a novel therapeutic approach for sarcopenia, though human trials remain essential. The strategy appears particularly promising because existing ghrelin receptor blockers already exist for other conditions, potentially accelerating clinical development for age-related muscle decline.
